A spokesperson for CVS Health said that the company would exclusively cover new migraine drugs from Eli Lilly and Teva, as reported NASDAQ Friday.

CVS spokeswoman Christine Cramer indicated that Teva's Ajovy and Eli Lilly's Emgality will be available for members who failed to respond to other preventative migraine treatments.

Under the decision, the pharmacy benefits manager will exclude Amgen's Aimovig from coverage.

An Amgen spokeswoman expressed that the drugmaker was disappointed by the move, adding that it planned to work to ensure that Aimovig is considered a preferred brand on CVS coverage lists.

Shares in Amgen were down 1.3 percent on the news, while shares in Teva jumped by the same percentage.

Register as Visitor to CPhI China 2019!